


Ifw



Patent Docket P1974R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  Baldwin et al.  Serial No.: 10/658,482  Filed: September 9, 2003  For: <i>Novel Composition and Methods for the Treatement of Immune Related Disease.</i>	Group Art Unit: 1644  Examiner: Szperka, Michael Edward  Confirmation: 3368  Customer No.: <b>09157</b>  <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on  September 20, 2005   Teri Lee
--	--

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**

In response to the Restriction Requirement dated August 31, 2005, issued in connection with the above application, please consider the following election and remarks.

In response to the outstanding Restriction Requirement, Applicants hereby provisionally elect the invention of Group I, specifically Claims 1-8 drawn to nucleic acids, vectors and host cells comprising SEQ ID NO:1, classified in class 536, subclass 23.5, and class 435, subclass 325. This election is made with without traverse.

The statutory period for reply is one month, therefore making this a timely reply. The Commissioner is authorized to charge any additional fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 07-0630.

The examiner is invited to contact the undersigned at (650) 225-3733 if any issues may be resolved in that manner.

Respectfully submitted,  
GENENTECH, INC.

Date: September 20, 2005

By: 

David A. Carpenter, Ph.D.  
Reg. No. 45,945

1 DNA Way, MS 49  
South San Francisco, CA 94080  
Phone: (650) 225-3733  
Fax: (650) 952-9881  
carpenda@gene.com